<DOC>
	<DOCNO>NCT00001577</DOCNO>
	<brief_summary>Hyperthermic isolate limb perfusion melphalan alone administer double perfusion schedule . These two isolates limb perfusion melphalan treat 3-6 week apart . After perfusion establish , leak rate determine acceptable , tissue temperature 38 degree Celsius , melphalan administer slow injection arterial line approximately 5 minute . The perfusion melphalan continue 60 minute , extremity flush total 3 liter fluid consist initially saline solution . The dose melphalan second perfusion increase . An attempt resect residual lesion 6-12 week second interval perfusion may make .</brief_summary>
	<brief_title>Pilot Study Double Isolation Perfusion Schedule Using Melphalan Alone Intransit Melanoma Unresectable Sarcoma Extremity</brief_title>
	<detailed_description>Patients extremity melanoma ( Stage IIIA , IIIAB Stage IV disease bulky symptomatic tumor locate extremity ) patient unresectable extremity sarcoma undergo double isolated limb perfusion melphalan alone separate approximately 4 6 week . The initial perfusion do melphalan dose 6 mg/L limb volume interval perfusion dose 9 mg/L limb volume . For patient extremity sarcoma tumor excise feasible use limb spar resection 6-12 week second perfusion . Technical feasibility double perfusion schedule determine . Overall response , duration response , pattern recurrence , survival follow .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm unresectable sarcoma intransit melanoma upper low extremity . Extremity sarcoma local resection option would require amputation base upon abutment proximity tumor major neurovascular structure bone joint structure . MELANOMA PATIENTS : Must history two satellite intransit metastases one may excise diagnosis exception patient single , large , deep , locally recurrent tumor metastatic tumor ( great 5 cm ) preclude excision primary closure . Stage IV melanoma must significant component ( great 90 % ) disease distal apex femoral triangle lower limb distal insertion deltoid upper limb . Must evaluable disease extremity . Melanoma must dermal subcutaneous lesion measure directly two diameter assess tumor burden . Sarcoma must either cutaneous lesion amenable direct measurement deeper lesion measure CT MRI scan . PRIOR/CONCURRENT THERAPY : At least 2 month since regional therapy affect extremity . BIOLOGIC THERAPY : At least 1 month since Biologic Therapy . CHEMOTHERAPY : At least 1 month since chemotherapy . ENDOCRINE THERAPY : Not specify . RADIOTHERAPY : At least 1 month since radiotherapy . SURGERY : Not specify . PATIENT CHARACTERISTICS : AGE : 18 . PERFORMANCE STATUS : ECOG 02 . LIFE EXPECTANCY : At least 6 month . HEMATOPOIETIC : Platelet count great 150,000/mm ( 3 ) . HEPATIC : Bilirubin le 2.0 mg/dL . RENAL : Creatinine le 2.0 mg/dL . CARDIOVASCULAR : No history congestive heart failure LVEF le 40 % . PULMONARY : No chronic obstructive pulmonary disease . No chronic pulmonary disease PFTs le 50 % predicted age . OTHER : IF HIV POSITIVE : Must CD4 cell count great 500/mL , No clinical manifestation AIDS . Coagulation parameter great 12 second within upper limit normal . No evidence severe peripheral vascular disease . No history claudication ischemic vascular disease . Not pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1999</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>Hyperthermia</keyword>
	<keyword>Isolation perfusion</keyword>
	<keyword>Regional Therapy</keyword>
</DOC>